Lia Kettenis
Child & Adolescent Psychiatry · Bloomington, INNPI 1346459146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$779
- Teva Pharmaceuticals USA, Inc.$693
- AbbVie$643
- Otsuka America Pharmaceutical, Inc.$595
- Alkermes, Inc.$496
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$467
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,555100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 27 | $779 |
| Teva Pharmaceuticals USA, Inc. | 38 | $693 |
| AbbVie(2 entities) | 34 | $643 |
| Otsuka America Pharmaceutical, Inc. | 29 | $595 |
| Alkermes, Inc. | 19 | $496 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $467 |
| Johnson & Johnson | 11 | $319 |
| Sunovion Pharmaceuticals Inc. | 20 | $240 |
| Axsome Therapeutics, Inc. | 5 | $235 |
| Vanda Pharmaceuticals Inc. | 3 | $186 |
| Supernus Pharmaceuticals, Inc. | 9 | $139 |
| Ironshore Pharmaceuticals Inc. | 6 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $100 |
| Tris Pharma Inc | 7 | $91 |
| Lundbeck LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Noven Therapeutics, LLC | 3 | $52 |
| Exact Sciences | 2 | $37 |
| Gilead | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Corium, LLC | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Orexo US, Inc. | 1 | $19 |
| Indivior Inc. | 1 | $17 |
| UCB, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,564 in reported general payments places this provider in the 90th percentile of 56 child & adolescent psychiatry providers in Indiana.
See all child & adolescent psychiatry providers in Indiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 12 | $41,059 |
| RexultiBrexpiprazole | 14 | $19,743 |
| VraylarCariprazine Hcl | 11 | $15,191 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $12,733 |
| Naltrexone Hcl | 75 | $8,692 |
| Clozapine | 81 | $8,629 |
| Aripiprazole | 65 | $7,465 |
| Quetiapine Fumarate | 133 | $5,927 |
| Olanzapine | 87 | $5,613 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $4,423 |
| Medroxyprogesterone Acetate | 16 | $4,401 |
| AmantadineAmantadine Hcl | 99 | $2,902 |
| Buspirone Hcl | 84 | $2,498 |
| Chlorpromazine Hcl | 26 | $2,274 |
| Guanfacine Hcl ErGuanfacine Hcl | 40 | $1,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $186 | $41,05912 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $595 | $19,74314 claims |
| AbbVieVraylar | $643 | $15,19111 claims |
| Axsome Therapeutics, Inc.Auvelity | $235 | $12,73314 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $693 | $62112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 56 child & adolescent psychiatry providers in Indiana.
Other child & adolescent psychiatry in Bloomington
- Sharon CurtisDyer$102K
- Christopher McDougleIndianapolis$17K
- Ann KledzikIndianapolis$12K
- Teresita Briones RamiloIndianapolis$7K
- Mitchell GoldsteinSouth Bend$6K
- Hugh StarksIndianapolis$4K
- Daniel KinseyGoshen$3K
- Michael WellingIndianapolis$3K
- Sanjay MishraCarmel$3K
- David PoseyIndianapolis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.